# X-Therma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/x-therma

- Industry: Biotechnology
- Headquarters: Hercules, US
- Website: www.x-therma.com
- Total disclosed funding: $35M
- Latest round: Series B (Mar 13, 2024)
- Investors on record: 8

## About

Based in California, US, and founded in 2014, X-Therma Inc. is a biotechnology company that engages in the development of a convergent biopreservation platform to advance regenerative medicine and organ preservation. In March 2024, X-Therma Inc. raised USD 22.4 million in series B funding co-led by investor Starling Ventures and investor LOREA AG.  The firm, as of August 2024, has offices in California, US, and Innsbruck, Austria, and is led by its co-founders Xiaoxi Wei (CEO) and Mark Kline (CTO).

X-Therma drew inspiration from antifreeze proteins found in arctic species to create non-toxic peptoids that prevent ice crystal formation, to the developer XT-Thrive® and XT-ViVo®, chemically defined cryopreservation media and organ preservation solutions, respectively. XT-Thrive® offers a DMSO-free, serum-free alternative for preserving mammalian cells at ultra-low temperatures, while XT-ViVo® maintains organ viability by mitigating ice-induced damage during storage. The company also offers TimeSeal®, a smart transporter designed to maintain optimal temperature stability during organ transport, ensuring safe and efficient delivery without external power sources.

The company plans to utilize the March 2024 funding to advance into the clinical stage and scale up its global commercial operations.

## Funding rounds

- Series B, Mar 13, 2024, $22M — Starling Ventures, LOREA AG
- Series A, Dec 17, 2021, $13M — Graphene Ventures, VU Venture Partners, Catalytic Impact Foundation, 2b AHEAD Ventures, LOREA AG, Methuselah Foundation, Zen11 Holdings

## Investors

- Graphene Ventures (https://capitalatlas.ai/funds/graphene-ventures) — Series A
- VU Venture Partners (https://capitalatlas.ai/funds/vu-venture-partners) — Series A
- Catalytic Impact Foundation (https://capitalatlas.ai/funds/catalytic-impact-foundation) — Series A
- 2b AHEAD Ventures (https://capitalatlas.ai/funds/2b-ahead-ventures) — Series A
- LOREA AG (https://capitalatlas.ai/funds/lorea-ag) — Series A, Series B
- Methuselah Foundation — Series A
- Zen11 Holdings (https://capitalatlas.ai/funds/zen11-holdings) — Series A
- Starling Ventures (https://capitalatlas.ai/funds/starling-ventures) — Series B